Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Cancer Res. 2013 Dec 5;74(4):1005–1010. doi: 10.1158/0008-5472.CAN-13-1911

Figure 1. Transgenic system of tamoxifen inducible, Cre mediated cell tracking with Trp53 deletion in CK19CreERTeYFPR26p53f/f mice.

Figure 1

(A) Transgenic construct of fluorescent labelling and tumour suppressor deletion in CK19 positive cells in response to tamoxifen in 6 week old mice. (B) In the presence of Cre and tamoxifen, eYFP activity is seen within small ductules as well as large bile ducts. The eYFP+ population expands following 14 days of dietary 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) (Scalebars: 50μm). Quantitative analysis of Cre efficiency 72 hours post injection in Cre negative mice exposed to tamoxifen (n=5), Cre positive mice without tamoxifen (n=3) and Cre positive mice exposed to tamoxifen (n=8). (C) Following tamoxifen injection eYFP positivity is seen only in CK19 expressing cells. These are cholangiocytes that also express the biliary markers Sox9. No co-localisation is seen with the mature hepatocyte marker Cyp2D6 (Scalebars: 50μm).